Drometrizole

Summary

Drometrizole (CHEMBL1564747) is a phase-3 clinical-stage small molecule.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Chemistry: 225.25 Da · C13H11N3O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1564747
Name	Drometrizole
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	17113
Molecular formula	C13H11N3O
Molecular weight	225.25
InChIKey	MCPKSFINULVDNX-UHFFFAOYSA-N

SMILES: CC1=CC(=C(C=C1)O)N2N=C3C=CC=CC3=N2

IUPAC name: 2-(benzotriazol-2-yl)-4-methylphenol

Also known as: Drometrizol, Drometrizole, NSC-91885, SID24800998, SID29218001, DROMETRIZOLE, SID144205922, SID144213883, SID144208074, SID170466144

Patent coverage: 15,985 distinct patent families (40,209 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 36,374 (90%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: Prelamin-A/C, NPC intracellular cholesterol transporter 1, Ras-related protein Rab-9A, Pyruvate kinase.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 5 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	6.2	Potency	631	nM	CHEMBL_ACT_3654666
RAB9A	5.5	Potency	3162	nM	CHEMBL_ACT_3876857
NPC1	5.5	Potency	3162	nM	CHEMBL_ACT_4709174

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).